This is a preview of subscription content, log in via an institution to check access.
Reference
Fang X, et al. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma. Frontiers in Oncology 12: 1024677, 22 Dec 2022. Available from: URL: http://www.frontiersin.org/Oncology/about
Rights and permissions
About this article
Cite this article
Pertuzumab/trastuzumab. Reactions Weekly 1945, 442 (2023). https://doi.org/10.1007/s40278-023-34523-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-34523-2